Elucidating the role of the IL-17A/miR-23b/versican pathway might enlarge our understanding of the interaction between inflammatory microenvironment and cancer progression, which can be exploited for potential immunotherapeutic and diagnostic target in TSCC. The gene discussed is IL17A; the disease is cancer.